Personalizing -Mutant Allele-Specific Therapies.

Chiara Falcomatà, Günter Schneider, Dieter Saur

Journal: Cancer discovery 2020;10(1):23-25

PMID: 31919121

Full Text on Silverchair Information Systems View on PubMed

Abstract

mutations occur almost exclusively in pancreatic ductal adenocarcinoma. The results of a study that reveals specific differences in KRAS downstream signaling and metabolic rewiring of pancreatic cancer cells harboring mutations promise to improve our possibilities to better stratify patients for individualized therapies..

Address: Division of Translational Cancer Research, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany.; Chair of Translational Cancer Research and Institute for Experimental Cancer Therapy, Klinikum rechts der Isar, School of Medicine, Technische Universität München, Munich, Germany.; Department of Internal Medicine II, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.; Division of Translational Cancer Research, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany. [email protected].

DOI: 10.1158/2159-8290.CD-19-1261

Link outs

Free resources

Medical:

https://medlineplus.gov/pancreaticcancer.html

Miscellaneous:

https://assays.cancer.gov/CPTAC-1550

Subscription / membership required

Full Text Sources:

https://aacrjournals.org/cancerdiscovery/article-l...

MeSH Terms: Alleles, Carcinoma, Pancreatic Ductal, Humans, Mutation, Pancreatic Neoplasms, Phosphatidylinositol 3-Kinases, Proto-Oncogene Proteins p21(ras)